2-(6-hydroxy-2-oxo-2H-chromen-4-yl)acetic acid | 68747-26-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 2-(6-hydroxy-2-oxo-2H-chromen-4-yl)acetic acid
• 英文别名: (6-hydroxy-2-oxo-2H-chromen-4-yl)-acetic acid；(6-Hydroxy-2-oxo-2H-chromen-4-yl)-essigsaeure；2-(6-hydroxy-2-oxochromen-4-yl)acetic acid
• CAS: 68747-26-2
• 化学式: C₁₁H₈O₅
• mdl: MFCD13196342
• 分子量: 220.182
• InChiKey: BFHNQOMHFVJCPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(6-hydroxy-2-oxo-2H-chromen-4-yl)acetic acid 在 18-冠醚-6 、 水 、 potassium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (2-(7-((4-azidobenzyl)oxy)-2-oxo-2H-chromen-4-yl)ethanoyl)glycine
  参考文献：
  名称：

  [EN] SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS
  [FR] LIBÉRATION SÉLECTIVE DE MÉDICAMENT À PARTIR DE CONJUGUÉS INTERNALISÉS DE COMPOSÉS BIOLOGIQUEMENT ACTIFS

  摘要：

  该发明涉及生物活性化合物的缀合物，其中所述缀合物包含一个氨基酸序列，该序列包含一个三肽，该三肽能够通过肿瘤组织匀浆选择性裂解以释放自由药物和/或与同一物种的正常组织匀浆相比，改善了药物在肿瘤组织中的生物分布，其中所述正常组织是与向需要治疗的人体受试者施用治疗有效量的比较缀合物相关的不良事件的发生部位，该比较缀合物的氨基酸序列是已知可被组织蛋白酶B选择性裂解的二肽。

  公开号：

  WO2021055865A1
• 作为产物：
  描述：

  3,3-bis-(2,5-dihydroxy-phenyl)-glutaric acid 在 硫酸 作用下， 生成 2-(6-hydroxy-2-oxo-2H-chromen-4-yl)acetic acid
  参考文献：
  名称：

  Dixit; Gokhale, Journal of the University of Bombay, Science: Physical Sciences, Mathematics, Biological Sciences and Medicine, 1934, vol. 3/, p. 80,91

  摘要：

  DOI：

文献信息

• Bernthsen synthesis, antimicrobial activities and cytotoxicity of acridine derivatives
  作者：Mehul M. Patel、Mimansha D. Mali、Saurabh K. Patel

  DOI：10.1016/j.bmcl.2010.06.001

  日期：2010.11

  The condensation reaction of diphenylamine with 2-oxo-2H-(substituted chromen)-4-yl acetic acid in presence of anhydrous zinc chloride afford 4-(acridine-9-ylmethyl)-2H-(substituted chromen)-2-one. The synthesized compounds were characterized by spectral studies and elemental analysis and screened for their in vitro antibacterial activity against Staphylococcus aureus, Staphylococcus pyogenes (gram (+)ve), Escherichia coli, Pseudomonas aeruginosa (gram -ve) and antifungal activity against Aspergillus niger and anticancer activity (HL-60, Hep-2 & HEK293T) by MTT assay. Chloro substituted compounds showed antimicrobial and anticancer activity with IC50 values in the low micromolar range. (C) 2010 Published by Elsevier Ltd.
• Dixit; Padukone, Journal of the Indian Chemical Society, 1950, vol. 27, p. 127,129
  作者：Dixit、Padukone

  DOI：——

  日期：——
• SHRIDHAR D. R.; SASTRY C. V. R.; VAIDYA N. K.; MOORTY S. R.; REDDI G. S.;+, INDIAN. J. CHEM., 1978, B16, NO 8, 704-708
  作者：SHRIDHAR D. R.、 SASTRY C. V. R.、 VAIDYA N. K.、 MOORTY S. R.、 REDDI G. S.、+

  DOI：——

  日期：——
• SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS
  申请人：Seagen Inc.

  公开号：US20210138077A1

  公开（公告）日：2021-05-13

  The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.
• [EN] SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS<br/>[FR] LIBÉRATION SÉLECTIVE DE MÉDICAMENT À PARTIR DE CONJUGUÉS INTERNALISÉS DE COMPOSÉS BIOLOGIQUEMENT ACTIFS
  申请人：SEAGEN INC

  公开号：WO2021055865A1

  公开（公告）日：2021-03-25

  The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.

  该发明涉及生物活性化合物的缀合物，其中所述缀合物包含一个氨基酸序列，该序列包含一个三肽，该三肽能够通过肿瘤组织匀浆选择性裂解以释放自由药物和/或与同一物种的正常组织匀浆相比，改善了药物在肿瘤组织中的生物分布，其中所述正常组织是与向需要治疗的人体受试者施用治疗有效量的比较缀合物相关的不良事件的发生部位，该比较缀合物的氨基酸序列是已知可被组织蛋白酶B选择性裂解的二肽。